University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Matthew Cooperberg, M.D.

Genitourinary cancer specialist

Dr. Matthew Cooperberg is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the diagnosis and management of genitourinary cancer, and using minimally invasive techniques to treat benign and malignant diseases. Cooperberg, who is interested in new technologies, performs robotic, laparoscopic, endoscopic and percutaneous surgeries. He developed a new prostate cancer risk assessment tool called the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score.

Cooperberg earned a medical degree and master's of public health at Yale University. He then completed training in general surgery and urology at UCSF, followed by a urologic oncology fellowship under the guidance of Dr. Peter Carroll. Cooperberg is a candidate member of the American Urological Association (AUA), Western Section of the AUA and the American College of Surgeons. He has written over 50 peer-reviewed scientific articles, nine chapters and has lectured nationally and internationally about malignant and benign urologic disease, with a particular focus on prostate cancer.

Clinics

Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Matthew Cooperberg

Additional Languages

Spanish

Education

Yale University School of Medicine 2000

Residencies

UCSF Medical Center, Urology 2008

Selected Research and Publications

  1. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6.
  2. Basto M, Cooperberg MR, Murphy DG. Proton therapy Websites: information anarchy creates confusion. BJU Int. 2015 Feb; 115(2):183-5.
  3. Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol. 2015 Jan; 25(1):65-70.
  4. Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015 Jan 20; 33(3):238-40.
  5. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
  6. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56.
  7. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  8. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific Variation in Outcomes for Men Treated With Primary Androgen Deprivation Therapy for Prostate Cancer. BJU Int. 2014 Sep 19.
  9. Cooperberg MR. Progress in Management of Low-risk Prostate Cancer: How Registries May Change the World. Eur Urol. 2015 Jan; 67(1):51-2.
  10. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry. Eur Urol. 2014 Sep 18.
  11. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014 Sep 16; 161(6):441-2.
  12. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. Eur Urol. 2014 Aug 28.
  13. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, Shariat SF, Vickers A. European urology: serving our readership through systematic peer review, use of reporting standards, and encouragement of postpublication review. Eur Urol. 2015 Feb; 67(2):188-90.
  14. Klein EA, Cooperberg MR, Carroll PR. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8.
  15. Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014 Nov 15; 120(22):3519-26.
  16. Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW. European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. Eur Urol. 2014 Oct; 66(4):628-32.
  17. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. Eur Urol. 2015 Feb; 67(2):326-33.
  18. Cooperberg MR. Implications of the new AUA guidelines on prostate cancer detection in the U.S. Curr Urol Rep. 2014 Jul; 15(7):420.
  19. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597.
  20. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.